Pediatrix Medical Group (NYSE:MD) Announces Earnings Results

Key Points

• Pediatrix exceeded quarterly expectations: The company reported EPS of $0.72 versus the $0.65 consensus estimate, while revenue rose 1.7% year over year to $501.37 million.
• Strong performance supports shareholder returns: Adjusted EBITDA reached $85 million, and management narrowed full-year 2026 guidance to $290 million–$300 million. Pediatrix also repurchased more than 3 million shares during the quarter while maintaining net leverage below one times adjusted EBITDA.
• Growth faces moderating tailwinds: Prior collection benefits are beginning to fade, tempering pricing growth, while operating costs continue to rise. The stock carries a consensus “Hold” rating with an average analyst price target of $26.60.

Pediatrix Medical Group (NYSE:MD - Get Free Report) posted its earnings results on Thursday. The company reported $0.72 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.65 by $0.07, FiscalAI reports. The business had revenue of $501.37 million for the quarter, compared to analysts' expectations of $498.18 million. Pediatrix Medical Group had a net margin of 8.96% and a return on equity of 20.05%. The business's revenue for the quarter was up 1.7% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.67 EPS.

Here are the key takeaways from Pediatrix Medical Group's conference call:

• Strong Q3 performance: Adjusted EBITDA reached $85 million, ahead of expectations, while same-unit revenue grew as volume and pricing each contributed positively. Management narrowed full-year 2026 adjusted EBITDA guidance to $290 million–$300 million.
• Shareholder returns and balance sheet: Pediatrix repurchased just over 3 million shares during the quarter, bringing cumulative buybacks since August 2025 to 10 million shares at an average price of $23. Net leverage remained below one times adjusted EBITDA, with $312 million of cash.
• Revenue tailwinds are moderating: The company is beginning to lap prior benefits from unusually strong collection activity, which reduced quarterly pricing growth by slightly more than 100 basis points. Operating costs continued to rise, although clinical salary growth remained relatively contained at roughly 3%–3.5%.
• Growth opportunities remain selective: Pediatrix is expanding telehealth and evaluating potential acquisitions in women’s and children’s healthcare, while monitoring 2027 OB hospitalist coding changes. Management said the No Surprises Act IDR process is unlikely to be a headwind because less than 5% of business is out-of-network.

Pediatrix Medical Group Stock Performance

Shares of Pediatrix Medical Group stock traded up $0.16 during trading hours on Thursday, reaching $29.07. 832,556 shares of the stock traded hands, compared to its average volume of 703,422. Pediatrix Medical Group has a one year low of $16.90 and a one year high of $30.55. The firm has a market capitalization of $2.36 billion, a price-to-earnings ratio of 13.91 and a beta of 0.61. The company has a quick ratio of 1.32, a current ratio of 1.32 and a debt-to-equity ratio of 0.45. The company has a 50 day moving average price of $26.86 and a 200 day moving average price of $23.82.

Analyst Ratings Changes

A number of analysts have recently commented on the stock. Jefferies Financial Group lowered shares of Pediatrix Medical Group from a "buy" rating to a "hold" rating and lifted their price target for the stock from $27.00 to $28.00 in a research note on Wednesday, August 19th. UBS Group increased their price objective on shares of Pediatrix Medical Group from $25.00 to $28.00 and gave the company a "neutral" rating in a research report on Thursday, August 6th. Wall Street Zen upgraded shares of Pediatrix Medical Group from a "buy" rating to a "strong-buy" rating in a research report on Sunday, September 13th. Weiss Ratings upgraded shares of Pediatrix Medical Group from a "hold (c+)" rating to a "buy (b-)" rating in a report on Wednesday, September 9th. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a "hold" rating and issued a $25.00 target price on shares of Pediatrix Medical Group in a research report on Wednesday, August 5th. One analyst has rated the stock with a Buy rating and five have assigned a Hold rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average price target of $26.60.

Pediatrix Medical Group Company Profile

Pediatrix Medical Group, Inc provides specialized physician-led healthcare services for women, infants and children. The company's clinical offerings include neonatal and perinatal care, maternal-fetal medicine, pediatric medical subspecialties, pediatric hospitalist services and related services delivered in partnership with hospitals and healthcare systems.

Pediatrix-affiliated physicians and advanced practice providers generally work in hospital-based settings, including neonatal intensive care units, delivery rooms, pediatric units and outpatient practices.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.